Table 2.
Quarterly incidence density for the main resistance phenotypes
| Time | Resistant strains/1000 patient-days | ||||||
|---|---|---|---|---|---|---|---|
| MRSA | ESBL E. coli |
ESBL K. pneumoniae |
ESBL P. mirabilis |
Combined-resistant P. aeruginosa a |
Carbapenem-resistant P. aeruginosa |
Carbapenem-resistant A. baumannii |
|
| Quarter I 2012 | 8.94 | 0.53 | 7.89 | 3.68 | 1.05 | 2.10 | 7.36 |
| Quarter II 2012 | 4.53 | 0.91 | 5.89 | 3.17 | 0.00 | 0.00 | 4.53 |
| Quarter III 2012 | 10.57 | 1.38 | 10.57 | 5.97 | 3.68 | 4.14 | 7.81 |
| Quarter IV 2012 | 4.13 | 2.29 | 8.26 | 5.05 | 0.92 | 1.38 | 6.42 |
| Quarter I 2013 | 8.76 | 0.92 | 2.77 | 2.77 | 3.23 | 3.69 | 7.84 |
| Quarter II 2013 | 7.60 | 0.95 | 5.23 | 3.33 | 2.85 | 3.80 | 5.70 |
| Quarter III 2013 | 5.02 | 1.83 | 7.76 | 1.83 | 5.48 | 5.48 | 5.02 |
| Quarter IV 2013 | 10.41 | 1.74 | 8.68 | 4.34 | 6.51 | 6.94 | 6.51 |
aResistance to three or more antimicrobial groups among ceftazidime, antipseudomonas penicillins, fluoroquinolones and aminoglycosides